BBOT NASDAQ
Credit Risk of going bust: lower than 64% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.8%), BridgeBio Oncology Therapeutics Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $215.7M.
Distance to default 6.68 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 71.5%; Altman Z'' 2.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cobo Marc | F-InKind | 203 | $2.68 | 2026-10-21 |
| Cobo Marc | F-InKind | 126 | $3.94 | 2026-10-01 |
| Elmelech Idan | F-InKind | 343 | $3.94 | 2026-10-01 |
| Beltran Pedro | F-InKind | 1,047 | $3.94 | 2026-10-01 |
| Ben Yong | F-InKind | 1,047 | $3.94 | 2026-10-01 |